I-BET151 selectively regulates IL-6 production

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Orchestration of the inflammatory response is crucial for clearing pathogens. Although the production of multiple inflammatory cytokines has been thought to be regulated by common mechanisms, recent evidence indicates that the expression of some cytokines is differentially regulated by epigenetic regulatory mechanisms. In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFα, IL-1β and IL-10) at the concentration of IBET151 used. I-BET151 prevented the binding of CBP to the promoter of IL-6, but I-BET151 did not affect acetylation, phosphorylation, nuclear translocation, or DNA binding of p65-NF-κB. In vivo, I-BET151 treatment in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis decreased the early clinical symptoms, which are thought to be dependent on cytokine production. Altogether, these data suggest that targeting epigenetic-related proteins, such as BET proteins, may provide a strategy to reduce inflammation and the severity of inflammatory diseases, such as multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)1549-1555
Number of pages7
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1842
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Cytokines
  • I-BET151
  • Lipopolysaccharide
  • Macrophage
  • NF-κB

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'I-BET151 selectively regulates IL-6 production'. Together they form a unique fingerprint.

Cite this